Coverage and access
BAFIERTAM® (monomethyl fumarate) delayed-release capsules cover 86% of all commercial lives.1
Not actual patient
BAFIERTAM is now covered for nearly 9 out of 10 patients on most commercial plans.1
143.2 million commercial patients are covered for BAFIERTAM,1 nearly 5 million more patients than Vumerity® (diroximel fumarate) delayed-release capsules at 138.6 million.1,2
Top national payers where BAFIERTAM is covered with no step edits:
| Health Plan/PBM1 | Covered Lives† |
|---|---|
| CVS Health (Aetna) | 49.4 million |
| Express Scripts, Inc | 28.5 million |
| Optum Rx | 29.1 million |
Co-Pay
97%
of BAFIERTAM patients enrolled in Cycle Vita™'s Co-Pay Program paid $0 out-of-pocket in 2025.3
55%
of those taking Vumerity.4
18%
of those taking generic dimethyl fumarate.4
References
1. Data on file: REF-00091.
2. Data on file: REF-00092.
3. Data on file: REF-00104.
4. Biogen. 2026. Patient coverage and access | VUMERITY® (diroximel fumarate). [online] Available at: https://www.vumerityhcp.com/en_us/home/access-and-support/access-and-support.html [Accessed: May 27 2026].
Vumerity® is a registered trademark of Biogen Inc.
*Patient may be required to try and fail preferred option before coverage for BAFIERTAM can be approved.
†Covered lives indicate all lives covered by the health plan/PBM, not just the number of patients who are covered for the specific therapeutic area. Not all member plans follow the national formulary.